West Pharmaceutical Services Inc

West Pharmaceutical Services Inc(WST)股票分析

$374.650

+2.847 (+0.76%)收盤時

Loading chart…
最高
379.210
開盤
372.210
成交量加權均價
375.36
成交量
444.57K
市值
23.95B
最低
372.210
成交金額
166.87M
企業價值/稅息折舊攤銷前利潤(TTM)
26.39

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

AI 分析 of West Pharmaceutical Services Inc (WST)

買進

West Pharmaceutical Services Inc is a good buy right now, trading at $366 with a forward P/E of 37.45, indicating strong growth potential. The company has shown a 39.44% increase over the past year and a 5.71% increase over the last 20 days, suggesting a positive momentum. Additionally, hedge funds have increased their buying activity by 196.32% over the last quarter, reflecting strong institutional confidence. However, the main risk is the RSI at 46.01, indicating that the stock is approaching oversold territory, which could lead to short-term volatility.

分析師評級(7)

-6.93% 下跌空間
買進
4 買進
2 持有
1 賣出
目前: 374.65
最低
285.00
平均
348.70
最高
375.00

Barclays

2026-10-07

目標價

$440

增持

Morgan Stanley

2026-09-22

目標價

$400

增持

UBS

2026-09-09

目標價

$415

買進

Citi

2026-08-03

目標價

$412

買進

Evercore ISI

2026-07-27

目標價

$425

優於大盤

估值指標

West Pharmaceutical Services Inc(WST)目前預期本益比為 37.04,5 年平均預期本益比為 41.23。

預期本益比

合理
5 年均值 P/E
41.23
目前P/E
37.04
高估
48.03
低估
34.43

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
26.84
目前EV/EBITDA
26.39
高估
31.76
低估
21.92

預期股價營收比

合理
5 年均值 P/S
7.51
目前P/S
7.29
高估
9.10
低估
5.93

Alphio AI 對 WST 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%WST

$201.68

情境價格

基

基準

基準 · 50%WST

$194.98

情境價格

悲

悲觀

悲觀 · 25%WST

$174.26

情境價格

持有 WST 的大戶

G

Generation Investment Management LLP

+ 持有WST

+9.98%

3個月報酬率

N

Nan Shan Life Insurance Co., Ltd.

+ 持有WST

+8.14%

3個月報酬率

C

Curi Capital, LLC

+ 持有WST

+7.45%

3個月報酬率

W

Walter Scott & Partners Limited

+ 持有WST

+6.75%

3個月報酬率

J

Jacobs Levy Equity Management Inc

+ 持有WST

+6.72%

3個月報酬率

R

Royal London Unit Trust Managers Limited

+ 持有WST

+5.79%

3個月報酬率

WST 常見問題 —— 由 Alphio AI 解答

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now, trading at $366 with a forward P/E of 37.45, indicating strong growth potential. The company has shown a 39.44% increase over the past year and a 5.71% increase over the last 20 days, suggesting a positive momentum. Additionally, hedge funds have increased their buying activity by 196.32% over the last quarter, reflecting strong institutional confidence. However, the main risk is the RSI at 46.01, indicating that the stock is approaching oversold territory, which could lead to short-term volatility.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易